Motor Learning in a Customized Body-Machine Interface

Status unconfirmed · Not applicable

Conditions studied: Spinal Cord Injury

In brief

People with tetraplegia often retain some level of mobility of the upper body. The proposed study will test the hypothesis that it is possible to develop personalized interfaces, which utilize the residual mobility to enable paralyzed persons to control computers, wheelchairs and other assistive devices. If successful the project will result into the establishment of a new family of human-machine interfaces based on wearable sensors that adapt their functions to their users' abilities.

Key facts

Study ID

NCT01608438

Run by

Shirley Ryan AbilityLab

People needed

157

Starts

2013-02-01

Expected to finish

2022-09-01

Last updated by the study team

2019-11-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-65
• Injuries at C3-C6 level, complete (ASIA A) or incomplete (ASIA B and C)
• Able to follow simple commands
• Able to speak or respond to questions

You may not qualify if…

• Presence of tremors, spasm and other significant involuntary movements
• Cognitive impairment
• Deficit of visuo-spatial orientation
• Concurrent pressure sores or urinary tract infection
• (Optional) Additional Exclusion Criteria for evaluation of corticospinal excitability using Transcranial Magnetic Stimulation:
• Any metal in head with the exception of dental work or any ferromagnetic metal elsewhere in the body. This applies to all metallic hardware such as cochlear implants, or an Internal Pulse Generator or medication pumps, implanted brain electrodes, and peacemaker.
• Personal history of epilepsy (untreated with one or a few past episodes), or treated patients
• Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
• Administration of drugs that potentially lower seizure threshold [62], without concomitant administration of anticonvulsant drugs which potentially protect against seizures occurrence
• Change in dosage for neuro-active medications (Baclophen, Lyrica, Celebrex, Cymbalta, Gapapentin, Naposyn, Diclofenac, Diazapam, Tramadol, etc) within 2 weeks of any study visit.
• Skull fractures, skull deficits or concussion within the last 6 months
• unexplained recurring headaches
• Sleep deprivation, alcoholism
• Claustrophobia precluding MRI
• Pregnancy

Where it is running

• Shirley Ryan AbilityLab — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.